Differential Susceptibility to DL-a-Difluoromethylornithine in Clinical Isolates of Trypanosoma Brucei Rhodesiense

Simple item page
dc.contributor.authorBacchi, C.J.en
dc.contributor.authorHenry, C.en
dc.contributor.authorNathan, H.C.
dc.contributor.authorLivingstone, T.
dc.contributor.authorValladares, G.
dc.contributor.authorSaric, M.
dc.contributor.authorSayer, P. D.
dc.contributor.authorNjogu, R.A.en
dc.contributor.authorAllen, B.en
dc.contributor.authorClarkson, A.B. jr
dc.contributor.institutionHaskin Laboratories and Department of Biology, Pace University, Department of Medical and Molecular Parasitology, New York University of Medical Center New York, Kenya Trypanosomiasesen
dc.date.accessioned2015-08-13T10:11:06Z
dc.date.available2015-08-13T10:11:06Z
dc.date.issued1990en
dc.description.abstractDL-alpha-Difluoromethylornithine is an enzyme-activated inhibitor of ornithine decarboxylase and an antagonist of polyamine metabolism that has been successful in clinical trials against West African sleeping sickness caused by Trypanosoma brucei gambiense. Its potential for use against the more virulent East African form of the disease, caused by T. brucei rhodesiense, is not certain. We examined 14 East African clinical isolates from the Kenya Trypanosomiasis Research Institute strain bank plus 2 established isolates for susceptibility to DL-alpha-difluoromethylornithine and to standard trypanocides. Seven of 16 strains were partially or totally refractory to DL-alpha-difluoromethylornithine in our test system. Four strains were also refractory to arsenical drugs, and five were refractory to diamidines. The results indicate that other novel agents or combinations of established agents may be needed for chemotherapy of East African disease.en
dc.description.sponsorshipPublic health Service , World bank, World health Organization, US Agency for International Developmenten
dc.identifier.citationBacchi, C.J., .Livington, T., Valladres, G., Saric, M., Sager, D.P., Njogu, R.A., Clarkson, B.A Jr (1990). Differential Susceptibility to DL-a-Difluoromethylornithine in Clinical Isolates of Trypanosoma brucei rhodesiense. Antimicrob Agents Chemother. Antimicrobial Agents and Chemotherapy, 34(6), 1183-1188. https://doi.org/10.1128/aac.34.6.1183 en
dc.identifier.doihttps://doi.org/10.1128/aac.34.6.1183 en
dc.identifier.urihttps://kalroerepository.kalro.org/handle/0/9492en
dc.language.isoenen
dc.publisherveterinary Recorden
dc.publisher.placeNairobien
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/en
dc.subject.agrovocTrypanosomaen
dc.subject.agrovocLaboratoriesen
dc.subject.agrovocBiologyen
dc.subject.agrovocInhibitionen
dc.titleDifferential Susceptibility to DL-a-Difluoromethylornithine in Clinical Isolates of Trypanosoma Brucei Rhodesienseen
dc.typeJournal Contribution*
dc.type.refereedRefereeden
dc.type.specifiedArticleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
REPRINTS 11 - 40 Split 9.pdf
Size:
504.01 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Animal Health

Social Media Links

  • Facebook
  • Flickr
  • Twitter
  • YouTube

Contact Us

Contact our us today. Our staff are ready to help you. There is no better time than now.
Learn How →

Our Address

Director General,
Kenya Agricultural and Livestock Research Organisation,
Post Office: P.O.Box 57811,
City Square, NAIROBI, 00200, Kenya
Kaptagat Rd, Loresho, Nairobi, Kenya
Direct Line : +254 722206986,
Contact Centre : 0111010100​

© 2024 KALRO · All Rights Reserved